Recent Company News

• 04:07 PM ET Oct 13, 2026
  

  Agomab announces first patient dosed in global NOV-ERA Phase 2B study of ontunisertib in Fibrostenosing Crohn's disease ($8.81, 0.00)

• 08:48 AM ET Oct 07, 2026
  

  Insider transaction: AgomAb Therapeutics NV CFO Pierre Kemula discloses purchase of 10.0K shares - Form 4 ($8.84, 0.00)

• 08:08 AM ET Oct 07, 2026
  

  Insider Tranasaction: AgomAb Therapeutics NV CEO Tim Knotnerus discloses purchase of 11K shares of common stock - Form 4 ($8.84, 0.00)

• 04:54 PM ET Aug 19, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:26 AM ET Aug 25, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:34 AM ET Oct 01, 2026
  

  Agomab reports topline data from STENOVA open-label extension study of ontunisertib in Fibrostenosing Crohn's disease ($11.10, 0.00)

• 04:09 PM ET Sep 14, 2026
  

  AgomAb Therapeutics NV announces positive results of phase 1 study of AGMB-447 in IPF patients ($12.28, 0.00)

• 04:14 AM ET Aug 25, 2026
  

  AgomAb Therapeutics NV initiated overweight at Piper Sandler ($12.82, 0.00)